Durbin Clinical Trial Comparator Supplies

Durbin is a specialist provider of comparator drugs for clinical trials. In addition to comparator drugs, Durbin also provides ancillary supplies and placebos. Durbin brings global sourcing expertise, transparent pricing and global custom distribution to the supply of comparators and ancillaries for clinical trials.

Durbin has over 45 years’ experience in sourcing pharmaceuticals and distributing them worldwide. Durbin combines this heritage with expertise in supplying comparators to pharmaceutical companies, both directly and via third parties, to bring a difference to the market.

Global sourcing expertise in comparator drug supply

Durbin buys direct from manufacturers and wholesalers. We have extensive and close relationships with all the top 30 pharmaceutical companies across Europe and North America. Sourcing from manufacturers and wholesalers guarantees pedigree and a reliable audit trail. We also supply placebos and ancillary items such as infusion pumps, non-PVC administration sets and infusions. We offer:

  • Any pack size
  • Single batch number
  • Any quantity
  • Same brands from multiple markets

Transparent pricing for clinical trial supply

Durbin is committed to openness throughout the supply process. We will share with you our cost price and negotiate with you a mutually acceptable profit margin. Sourcing generically can offer up to 80% discount on branded list price. Durbin works closely with all generic companies to negotiate substantial discounts for our clients. We offer:

  • Transparency in costing
  • Invoices provided for all costs
  • Negotiated profit margins
  • Partnership approach

Global bespoke distribution for clinical trial comparators

Durbin’s expertise in distribution ensures we can deliver clinical trial comparators to trial centres across the world, including China, Russia and India. We can deliver any amount and supply Europe within 24 hours. Having multi-lingual account managers enables us to negotiate directly with importation authorities to reduce duty payments and delays. The languages spoken by our team include Cantonese, Mandarin, Russian, Hindi, Spanish, French and German.

Benefits of our clinical trial comparator supply service include:

  • Frequent deliveries to over 180 countries
  • Cold chain and ambient supply chain
  • Fully tracked deliveries including temperature control
  • Specialised logistics team

Expertise in oncology, cold chain and high-value comparator drugs

Durbin has built a reputation of being able to source and supply oncology, cold chain and high-value comparator drugs quickly, efficiently and at lower than normal costs. We will devise sourcing and distribution strategies to lower the costs of clinical trial supply.

Clinical trial supply partners to the global pharmaceutical industry and specialised biotech companies

Durbin has extensive contracts and partnerships with the top 30 global pharmaceutical companies and research-based biotech companies. We can advise on all areas of clinical trial supply and logistics.

Make an enquiry

Durbin PLC

180 Northolt Road

South Harrow




United Kingdom

+44 20 8869 6525 +44 20 8869 6563 www.durbin.co.uk/clinical_trials.htm

Durbin Images

Products and Services


White Papers

Related Projects

Alofisel (darvadstrocel) for the Treatment of Complex Perianal Fistulas in Crohn’s Disease

Alofisel® (formerly Cx601 / darvadstrocel) is the first allogeneic stem cell therapy to be approved for the treatment of complex perianal fistulas in adult patients with Crohn’s disease.

20th April 2018

Zinbryta (daclizumab) for the Treatment of Multiple Sclerosis

Zinbryta (daclizumab) is an injectable formulation jointly developed by Biogen and Abbive for the treatment of relapsing forms of multiple sclerosis (MS) in adults.

22nd March 2018

Herzuma (trastuzumab biosimilar) for the Treatment of Breast and Gastric Cancers

Herzuma® (trastuzumab biosimilar / CT-P6) is indicated for the treatment of human epidermal growth factor receptor 2 (HER2) overexpressing breast cancer and metastatic gastric cancer.

20th February 2018

Biktarvy for the Treatment of HIV-I

Biktarvy® is a once-daily regimen indicated for the treatment of HIV-1 infection in adults that were previously not treated with anti-retroviral medicines.

19th February 2018

Bevyxxa (betrixaban) for the Treatment of Venous Thromboembolism (VTE) in Adults

Bevyxxa (betrixaban) is a drug developed by Portola Pharmaceuticals that is indicated for the prevention and treatment of venous thromboembolism (VTE) in adults.

2nd January 2018

Lartruvo (olaratumab) for the Treatment of Soft Tissue Sarcoma

Developed by Eli Lilly and Company, Lartruvo (olaratumab) in combination with doxorubicin is indicated for the treatment of soft tissue sarcoma (STS) in adult patients. The drug is available as a 10mg/ml injection.

13th September 2017

Dinutuximab beta for the Treatment of Neuroblastoma

Dinutuximab beta is an anti-GD2 monoclonal antibody indicated for the treatment of neuroblastoma in patients aged one year and above.

18th May 2017

Zejula (niraparib) for the Treatment of Ovarian Cancer

Zejula™ (niraparib) is a poly adenosine diphosphate (ADP) ribose polymerase (PARP) inhibitor approved for the treatment of adult patients with ovarian cancer.

9th April 2017

Translarna (ataluren) for the Treatment of Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD)

Translarna™ (ataluren) is a protein restoration therapy indicated for the treatment of nonsense mutation Duchenne muscular dystrophy (nmDMD). The drug was developed by PTC Therapeutics.

2nd April 2017

Kisqali® (ribociclib) for the Treatment of HR+/HER2- Metastatic Breast Cancer

Formerly known as LEE011, Kisqali® (ribociclib) is a cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitor indicated for the treatment of hormone receptor positive, human epidermal growth factor receptor 2 negative (HR+/HER2-) metastatic breast cancer in post-menopausal women.

15th March 2017

Afluria Quadrivalent for Prevention of Infection from Influenza Virus

Afluria Quadrivalent is an inactivated influenza vaccine developed by Seqirus, which is developed to provide active immunisation against the disease.

13th September 2016

Halaven (eribulin mesylate) for the Treatment of Advanced Liposarcoma

Halaven (eribulin mesylate) is an injectable chemotherapy drug developed by Eisai for the treatment of unresectable or metastatic liposarcoma patients that previously received anthracycline-based chemotherapy.

11th February 2016

Darzalex (daratumumab) for the Treatment of Multiple Myeloma

Darzalex (daratumumab) is the world's first human anti-CD38 monoclonal antibody (mAb) approved for the treatment of patients with multiple myeloma.

3rd February 2016

Aristada™ (aripiprazole lauroxil) for the Treatment of Schizophrenia

Aristada™ (aripiprazole lauroxil), discovered and developed by Alkermes, is an antipsychotic drug indicated for the treatment of schizophrenia in adults.

19th October 2015

Press Release

Regional Offices

Durbin PLC

180 Northolt Road

South Harrow




United Kingdom

+44 20 8869 6525 +44 20 8869 6563 www.durbin.co.uk/clinical_trials.htm

Go Top